Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

TXMD , T.HLS , T.CTX , T.GUD , V.XRTX , T.CRDL , T.APLI
Sort by: Date|Relevance

XPhyto: Innovating a Therapeutic Psychedelic Drug Pipeline

It’s been dubbed the Age of Anxiety. Yet it’s quickly becoming far worse than that. With the arrival of globalism, the new millennium has already become synonymous with the threat of deadly pandemics. And the onslaught of the worst of them s...
Marc Davis | January 20, 2021 |

Biopharma Makes Licensing Deal for Therapeutic Rights in Japan

The company's reasons for the transaction and expected short-term, stock-moving events are provided in a ROTH Capital Partners report. In a Sept. 9 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Eidos Therapeutics Inc. (EIDX:NASDAQ) agreed...
Streetwise Reports | September 12, 2019 |

Biotech's DMD Therapeutic 'Solidifies the Ground for Potential Pivotal Design'

The latest development concerning this clinical asset and other Q2/19 highlights are provided in an H.C. Wainwright & Co. report. In an Aug. 8 research note, analyst Joseph Pantginis reviewed Capricor Therapeutics Inc.'s (CAPR:NASDAQ) Q2/19 financials and reported t...
Streetwise Reports | August 14, 2019 |

Biopharma Receives FDA Fast Track Designation for Cancer Therapeutic

An explanation of the categorization and its implications are provided in a Paradigm Capital report. In a May 30 research note, Paradigm Capital analyst Rahul Sarugaser reported that Zymeworks Inc.'s (ZYME:NYSE; ZYME:TSX) lead product candidate ZW25 wa...
Streetwise Reports | June 10, 2019 |

Biopharma's Brain Cancer Therapeutic Compelling, Its Stock Undervalued

A description of the asset and its potential are provided in a Dawson James report. In a July 11 research note, Dawson James Securities analyst Jason Kolbert reported that coverage of DelMar Pharmaceuticals Inc. (DMPI:NASDAQ) transferred to him and, subseq...
Streetwise Reports | July 19, 2019 |

XPhyto: The Cutting Edge of Medical Cannabis Science

At the forefront of the next wave of cannabis commercialization, is a German-focused company with headquarters in Vancouver, XPhyto Therapeutics Corp. (CSE: XPHY; FSE: 4XT) , that is building a much-coveted cannabis R&D cultivation facility in a converted nuclear bunker and o...
Marc Davis | November 12, 2019 |

InMed Shares Trade Up 25% After Becoming First to Advance Cannabinol into Clinical Trials

InMed Pharmaceuticals shares traded 25% higher after reporting that it is the first to advance cannabinol into therapeutic clinical trials. Vancouver-based clinical stage biopharmaceutical company InMed Pharmaceuticals Inc. (IN:TSX; IMLFF:OTCQX) , which is engaged in...
Streetwise Reports | January 21, 2020 |

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data

Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher today after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. This morning clinical-stag...
Streetwise Reports | November 19, 2019 |

Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress

A description of Mesoblast's multi-site clinical trial and possible implication for the therapeutic are provided in an H.C. Wainwright & Co. report.
Streetwise Reports | May 14, 2020 |

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...
Knox Henderson | March 20, 2024 |
1 2 3 4 5 6 7 8 9 10 ...